These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 37840917)

  • 1. Exploring the causes of augmentation in restless legs syndrome.
    Zeng P; Wang T; Zhang L; Guo F
    Front Neurol; 2023; 14():1160112. PubMed ID: 37840917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation.
    Earley CJ; Uhl GR; Clemens S; Ferré S
    Sleep Med; 2017 Mar; 31():71-77. PubMed ID: 27539027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute.
    García-Borreguero D; Allen RP; Kohnen R; Högl B; Trenkwalder C; Oertel W; Hening WA; Paulus W; Rye D; Walters A; Winkelmann J; Earley CJ;
    Sleep Med; 2007 Aug; 8(5):520-30. PubMed ID: 17544323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aripiprazole, a Novel Option in the Management of Restless Legs Syndrome (RLS) Patients with Augmentation and/or Severe RLS Symptoms: A Report of 4 Cases.
    Lee EK; Spitale N; Robillard R
    Nat Sci Sleep; 2023; 15():779-784. PubMed ID: 37818170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restless Legs Syndrome: From Pathophysiology to Clinical Diagnosis and Management.
    Guo S; Huang J; Jiang H; Han C; Li J; Xu X; Zhang G; Lin Z; Xiong N; Wang T
    Front Aging Neurosci; 2017; 9():171. PubMed ID: 28626420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation.
    Garcia-Borreguero D; Silber MH; Winkelman JW; Högl B; Bainbridge J; Buchfuhrer M; Hadjigeorgiou G; Inoue Y; Manconi M; Oertel W; Ondo W; Winkelmann J; Allen RP
    Sleep Med; 2016 May; 21():1-11. PubMed ID: 27448465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BTBD9 and dopaminergic dysfunction in the pathogenesis of restless legs syndrome.
    Lyu S; Doroodchi A; Xing H; Sheng Y; DeAndrade MP; Yang Y; Johnson TL; Clemens S; Yokoi F; Miller MA; Xiao R; Li Y
    Brain Struct Funct; 2020 Jul; 225(6):1743-1760. PubMed ID: 32468214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.
    Bogan RK
    Clin Ther; 2014 Mar; 36(3):436-55. PubMed ID: 24636821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and treatment of augmentation in patients with restless legs syndrome: practical recommendations.
    Geyer J; Bogan R
    Postgrad Med; 2017 Sep; 129(7):667-675. PubMed ID: 28818004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restless legs syndrome in the older adult: diagnosis and management.
    Milligan SA; Chesson AL
    Drugs Aging; 2002; 19(10):741-51. PubMed ID: 12390051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pathophysiology of restless legs syndrome].
    Miyamoto M; Miyamoto T; Iwanami M; Suzuki K; Hirata K
    Brain Nerve; 2009 May; 61(5):523-32. PubMed ID: 19514512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome.
    Paulus W; Trenkwalder C
    Lancet Neurol; 2006 Oct; 5(10):878-86. PubMed ID: 16987735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restless legs syndrome: From clinic to personalized medicine.
    Chenini S; Barateau L; Dauvilliers Y
    Rev Neurol (Paris); 2023 Oct; 179(7):703-714. PubMed ID: 37689536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment with dopamine D3 receptor agonists induces a behavioral switch that can be rescued by blocking the dopamine D1 receptor.
    Dinkins ML; Lallemand P; Clemens S
    Sleep Med; 2017 Dec; 40():47-52. PubMed ID: 29221778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of treatment failure in restless legs syndrome (Willis-Ekbom disease).
    Garcia-Borreguero D; Cano-Pumarega I; Marulanda R
    Sleep Med Rev; 2018 Oct; 41():50-60. PubMed ID: 29602660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D and Restless Legs Syndrome: A Review of Current Literature.
    Cederberg KLJ; Silvestri R; Walters AS
    Tremor Other Hyperkinet Mov (N Y); 2023; 13():12. PubMed ID: 37034443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating Severe Refractory and Augmented Restless Legs Syndrome.
    Winkelman JW
    Chest; 2022 Sep; 162(3):693-700. PubMed ID: 35609673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of restless legs syndrome.
    Rios Romenets S; Postuma RB
    Curr Treat Options Neurol; 2013 Aug; 15(4):396-409. PubMed ID: 23703310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Concepts of the Pathophysiology and Adverse Outcomes of Restless Legs Syndrome.
    Romero-Peralta S; Cano-Pumarega I; García-Borreguero D
    Chest; 2020 Sep; 158(3):1218-1229. PubMed ID: 32247713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Treatment of Restless Legs Syndrome (RLS): An Approach to Management of Worsening Symptoms, Loss of Efficacy, and Augmentation.
    Mackie S; Winkelman JW
    CNS Drugs; 2015 May; 29(5):351-7. PubMed ID: 26045290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.